---
document_datetime: 2024-08-21 15:24:42
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/raxone-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: raxone-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 5.8244701
conversion_datetime: 2025-12-26 17:34:41.12913
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Raxone

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0040/G            | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or | 26/06/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|             | material/intermediate B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue                                                                                                                                                                                                                                                            |            |     |                       |               |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|---------------|
| IB/0037/G   | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method A.7 - Administrative change - Deletion of | 07/05/2024 | n/a |                       | manufacturing |
| IAIN/0039/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings                                                                                                                                                                              | 23/04/2024 |     | SmPC, Annex II and PL |               |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |            |                        |                                                                                                                                                                                                                                                                 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10412 /202309 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/04/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IA/0038             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                           | 11/03/2024 | n/a        |                        |                                                                                                                                                                                                                                                                 |
| S/0035              | 8th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/02/2024 | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Raxone should be maintained. |
| T/0034              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/09/2023 | 19/10/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| PSUSA/10412 /202209   | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                             | 14/04/2023   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0032                | 7th annual re-assessment                                                                                                                                                                                                                                                                            | 23/02/2023   | n/a        |                       | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Raxone should be maintained. |
| II/0031               | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                   | 21/07/2022   | 07/07/2023 | SmPC and Annex II     |                                                                                                                                                                                                                                                                 |
| S/0029                | 6th annual re-assessment                                                                                                                                                                                                                                                                            | 19/05/2022   | 15/07/2022 | SmPC, Annex II and PL | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Raxone should be varied.     |
| PSUSA/10412 /202109   | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                             | 07/04/2022   | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0028               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                       | 21/07/2021   | 15/07/2022 | Annex II              |                                                                                                                                                                                                                                                                 |
| IB/0027/G             | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished | 25/05/2021   | n/a        |                       |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10412 /202009 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 09/04/2021 | n/a | PRAC Recommendation - maintenance |
| S/0023              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/03/2021 | n/a |                                   |
| IB/0024/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any                                                                                                                                                                                     | 06/01/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| R/0020              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/05/2020 | 06/08/2020 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10412 /201909 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/04/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| S/0019              | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Raxone should be maintained.                                                                                                                                                                                                                                                                                      | 27/02/2020 | n/a        |                                  |                                   |
| II/0018             | Submission of the final report from study SNT-EAP- 001 listed as a Specific Obligation (SOB11, former SOB4) in the Annex II of the Product Information. This is a follow-up study of patients in the Expanded Access Program (SNT-EPA-001) for Raxone in the treatment of patients with Leber's Hereditary Optic Neuropathy (LHON). The goal is to collect further long-term real-world efficacy and safety data. Annex II is modified accordingly. An updated RMP version 1.9 submitted accordingly. The requested variation proposed amendments to | 14/11/2019 | 04/05/2020 | Annex II                         |                                   |

<div style=\"page-break-after: always\"></div>

|                     | (RMP). C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation   |            |            |           |                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation          | 17/10/2019 | 04/05/2020 | Annex II  | The applicant submitted final results from the SNT-CRS- 002 listed as a Specific Obligation (SOB10, former SOB2) which is a Historical case record survey (CRS) of visual acuity data from patients with Leber's hereditary optic neuropathy (LHON) to be used as the external control to the open label study. After completion of the SOB, this SOB was deleted from Annex IIE in the PI as well as from the RMP. |
| IAIN/0017           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                     | 27/08/2019 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0015             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation          | 28/05/2019 | 04/05/2020 | Annex II  |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10412 /201809 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                | 11/04/2019 | n/a        |           | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                   |
| S/0012              | Annual re-assessment.                                                                                                                                  | 28/02/2019 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| N/0014              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                       | 11/12/2018 | 07/02/2019 | Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IAIN/0011/G         | This was an application for a group of variations.                                                                                                     | 19/10/2018 | n/a        |           |                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                     | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10412 /201709 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/04/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0008             | Update of SmPC section 4.5 to amend an existing warning in relation to CY3A4 substrates based on the final report of study SNT-I-017: An open-label study to assess the potential for pre-systemic inhibition of cytochrome P450 3A4 (CYP3A) by idebenone in healthy male subjects using midazolam as a substrate. The Package Leaflet was updated accordingly. An updated RMP version 1.5 was submitted as part of the application. The provision of the study report addresses the post-authorisation measure MEA 005.1.                                                                                  | 08/03/2018 | 07/02/2019 | SmPC and PL | In vivo idebenone is a mild inhibitor of CYP3A4. Data from a drug-drug interaction study in 32 healthy volunteers indicate that on the first day of oral administration of 300 mg idebenone t.i.d., the metabolism of midazolam, a CYP3A4 substrate, was not modified when both drugs were administered together. After repeated administration Cmax and AUC of midazolam were increased by 28% and 34%, respectively, when midazolam was administered in combination with 300 mg idebenone t.i.d. Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                      |            |            |      | tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving idebenone.                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0009              | 2nd annual re-assessment                                                                                                                                                                                               | 22/02/2018 | n/a        |      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Raxone should be maintained.     |
| S/0005              | 1st Annual Re-assessment                                                                                                                                                                                               | 21/04/2017 | n/a        |      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the Marketing Authorisation of Raxone should be maintained. |
| IB/0007             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                          | 18/04/2017 | n/a        |      |                                                                                                                                                                                                                                                                     |
| PSUSA/10412 /201609 | Periodic Safety Update EU Single assessment - idebenone (centrally authorised products)                                                                                                                                | 06/04/2017 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                   |
| IA/0004             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                          | 12/08/2016 | 19/07/2017 | SmPC |                                                                                                                                                                                                                                                                     |
| II/0002             | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product | 28/04/2016 | n/a        |      |                                                                                                                                                                                                                                                                     |